导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 8.97% | 636/3266 |
| 近一周 | -2.03% | 2186/3690 |
| 近一月 | -3.34% | 1605/3663 |
| 近一季 | -0.31% | 725/3534 |
| 近半年 | 0.01% | 960/3357 |
| 近一年 | 17.76% | 486/3056 |
| 近两年 | 83.41% | 593/2167 |
| 近三年 | 66.22% | 291/1638 |
| 成立以来 | 185.80% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.17% 794/4961 |
9.59% 2477/5312 |
- - |
- - |
| 2025 | 39.12% 841/4813 |
1.75% 1558/3635 |
5.74% 549/4076 |
28.66% 1255/4524 |
0.51% 1963/4813 |
| 2024 | 18.75% 579/3463 |
2.55% 754/2808 |
4.02% 237/3014 |
13.00% 2262/3129 |
-1.49% 1723/3463 |
| 2023 | -6.53% 852/2656 |
4.68% 888/2280 |
-1.84% 533/2385 |
-1.37% 511/2515 |
-7.78% 2208/2655 |
| 2022 | -6.42% 128/2207 |
-2.83% 155/1919 |
2.87% 1243/2016 |
-8.77% 225/2113 |
2.62% 880/2208 |
| 2021 | 23.51% 129/1822 |
7.79% 68/1255 |
10.41% 465/1330 |
2.82% 428/1466 |
0.94% 1038/1822 |
| 2020 | 36.75% 387/1250 |
-3.95% 331/1028 |
19.95% 288/1067 |
10.58% 534/1164 |
7.34% 716/1184 |
| 2019 | - - |
- - |
- - |
- - |
5.18% 739/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 浙商之江凤凰ETF VS. 长安沪深300非周期A(740101) |